A Study of CBX-250 in Participants With Relapsed or Refractory Myeloid Leukemias

Study CBX-250-001 is a Phase 1, open-label, dose-escalation study of CBX-250 in participants with relapsed/refractory AML, HR-MDS, CMML, and CML. Participants aged ≥ 12 years are planned to be enrolled. CBX-250 will initially be investigated on a fixed step-up dosing schedule. CBX-250 will be administered subcutaneously in 28-day cycles, with the first study drug dose administered on Cycle 1, Day 1. Cycle 1 will consist of a priming phase over 7 days, and a target phase over 28 days. Participants will continue CBX-250 until progressive disease (PD) or unacceptable toxicity. All subsequent trea

Trial Details

NCT ID
NCT06994676
Phase
PHASE1
Sponsor
Crossbow Therapeutics, Inc.
Status
RECRUITING
Cancer Type
Leukemia
Interventions
  • CBX-250
Locations (sample)
  • Duarte, California, United States|34.13945,-117.97729
  • Palo Alto, California, United States|37.44188,-122.14302
  • Tampa, Florida, United States|27.94752,-82.45843
  • Chicago, Illinois, United States|41.85003,-87.65005
  • Boston, Massachusetts, United States|42.35843,-71.05977

Key Eligibility Criteria

  • Participants are eligible to be included in the study only if all of the following criteria apply:
  • Dose Escalation: Male or female participants aged ≥18 years.
  • Backfill Cohorts: Male or female participants aged ≥12 years for whom no curative treatment options, including transplantation, are available.
  • Diagnosis \& Disease Characteristics

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Leukemia Trials on Trialify →